When was STAR Therapeutics founded?

STAR Therapeutics was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Where is STAR Therapeutics located?

STAR Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of STAR Therapeutics?

Adam Rosenthal of STAR Therapeutics. They have also founded 2 companies.

How many employees does STAR Therapeutics have?

As of Mar 31, 2026, the latest employee count at STAR Therapeutics is 57.

Is STAR Therapeutics a funded company?

STAR Therapeutics is a funded company, having raised a total of $215M across 2 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Sep 05, 2023.

When was the latest funding round of STAR Therapeutics?

STAR Therapeutics' latest funding was a $***** Series D round on Sep 30, 2025, with participation from 17 investors. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $870M in funding in 2026 to date.

Where does STAR Therapeutics rank among its competitors?

STAR Therapeutics ranks 45th amongst 2534 active competitors, of which 881 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of STAR Therapeutics?

STAR Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

STAR Therapeutics - 2026 Company Profile, Team, Funding & Competitors

STAR Therapeutics is a series D company based in San Francisco (United States), founded in 2018 by Adam Rosenthal. It operates as a Developer of antibody therapies for multiple diseases. STAR Therapeutics has raised $215M in funding from investors like Sofinnova Investments, Viking Global Investors and Sanofi Ventures. The company has 2534 active competitors, including 881 funded and 628 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Developer of antibody therapies for multiple diseases. The company is developing antibody drug discovery to generate drug programs that target multiple diseases with a single therapy. Its lead candidate ELA026 is a monoclonal antibody specifically designed to address severe inflammatory disorders. The company is addressing drugs for immunology, immuno-oncology, and rare hematologic diseases.

Website: star-therapeutics.com
Social
Email ID: *****@star-therapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Series D

Total Funding

$215M in 2 rounds

Latest Funding Round

Series D, Sep 30, 2025, $*****

Investors

Sofinnova Investments & 18 more

Ranked

45^th among 2534 active competitors

Employee Count

57 as on Mar 31, 2026

Investment & Acquisitions

Vega

Similar Companies

Dren Bio & 198 more

View STAR Therapeutics' full profile

STAR Therapeutics has raised a total funding of $215M over 2 rounds. Its first funding round was on Sep 05, 2023. Its latest funding round was a Series D round on Sep 30, 2025 for $*****. 17 investors participated in its latest round. STAR Therapeutics has 19 institutional investors.

Here is the list of recent funding rounds of STAR Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2025	3249098	Series D	7345751	4269237	1135169	1760647
Sep 05, 2023	9945760	Series C	4354172	9196299	Sofinnova Investments	Agent Capital & 11 more

Access funding benchmarks and valuations. Sign up today!

View details of STAR Therapeutics's funding rounds and investors

The founders of STAR Therapeutics is Adam Rosenthal. Adam Rosenthal is the CEO of STAR Therapeutics.

Here are the details of STAR Therapeutics' key team members:

Adam Rosenthal: Founder & CEO of STAR Therapeutics and founder of 1 other company.
Contact Info: 1 email address

View details of STAR Therapeutics's Founder profiles and Board Members

STAR Therapeutics' employee count trend

STAR Therapeutics has 57 employees as of Mar 26. Here is STAR Therapeutics's employee count trend over the years:

Employee count trend for STAR Therapeutics

Uncover STAR Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of STAR Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of STAR Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	73/100
4th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
45th	STAR Therapeutics 2018, San Francisco (United States), Series D	Developer of antibody therapies for multiple diseases	$215M	RA Capital Management, Cowen & 17 others	66/100